Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOLIS
NCT07844759Not yet recruiting
- Sponsor
- Renaissance Institute of Precision Oncology & Radiosurgery
- Start
- Jan 2027
- Primary completion
- Jan 2029
- Countries
- 1
01
Overview
Open-label, single-arm trial in breast cancer, sponsored by Renaissance Institute of Precision Oncology & Radiosurgery. Primary endpoint: Incidence of CTCAE v5.0 Grade >=2 skin adverse events at 90 days. Planned start Jan 2027; status: not yet recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07844759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07844759.